Analysts Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Target Price at $10.33

Niagen Bioscience, Inc. (NASDAQ:NAGE) has earned an average recommendation of “Buy” from the five research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $10.3333.

NAGE has been the topic of a number of recent analyst reports. Roth Capital reaffirmed a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. Freedom Capital upgraded shares of Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th. Canaccord Genuity Group cut their target price on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. HC Wainwright reissued a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Friday, July 17th.

Niagen Bioscience Stock Performance

NAGE stock opened at $3.13 on Friday. The business’s 50-day moving average is $3.27 and its 200 day moving average is $3.98. The stock has a market cap of $249.27 million, a price-to-earnings ratio of 17.39 and a beta of 2.09. Niagen Bioscience has a 12-month low of $2.87 and a 12-month high of $10.52.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analysts’ expectations of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. As a group, equities analysts forecast that Niagen Bioscience will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. purchased a new position in Niagen Bioscience in the 3rd quarter worth approximately $37,522,000. SteelPeak Wealth LLC bought a new stake in Niagen Bioscience during the first quarter worth approximately $14,875,000. Arrowstreet Capital Limited Partnership raised its holdings in Niagen Bioscience by 47.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock valued at $10,489,000 after buying an additional 761,685 shares during the period. Tieton Capital Management LLC bought a new stake in Niagen Bioscience in the second quarter worth about $6,407,000. Finally, UBS Group AG grew its holdings in shares of Niagen Bioscience by 18.0% in the fourth quarter. UBS Group AG now owns 1,411,742 shares of the company’s stock worth $8,979,000 after purchasing an additional 215,645 shares during the last quarter. Institutional investors own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.